{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:22:19Z","timestamp":1791350539902,"version":"4.3.1"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Ross River virus (RRV) is endemic in Australia and several South Pacific Islands. More than 90,000 cases of RRV disease, which is characterized by debilitating polyarthritis, were reported in Australia in the last 20 years. There is no vaccine available to prevent RRV disease. A phase 3 study was undertaken at 17 sites in Australia to investigate the safety and immunogenicity of an inactivated whole-virus Vero cell culture-derived RRV vaccine in 1,755 healthy younger adults aged 16 to 59 years and 209 healthy older adults aged \u226560 years. Participants received a 2.5-\u03bcg dose of Al(OH)<jats:sub>3<\/jats:sub>-adjuvanted RRV vaccine, with a second and third dose after 3 weeks and 6 months, respectively. Vaccine-induced RRV-specific neutralizing and total IgG antibody titers were measured after each immunization. Vaccine safety was monitored over the entire study period. The vaccine was safe and well-tolerated after each vaccination. No cases of arthritis resembling RRV disease were reported. The most frequently reported systemic reactions were headache, fatigue, and malaise; the most frequently reported injection site reactions were tenderness and pain. After the third immunization, 91.5% of the younger age group and 76.0% of the older age group achieved neutralizing antibody titers of \u22651:10; 89.1% of the younger age group and 70.9% of the older age group achieved enzyme-linked immunosorbent assay (ELISA) titers of \u226511 PanBio units. A whole-virus Vero cell culture-derived RRV vaccine is well tolerated in an adult population and induces antibody titers associated with protection from RRV disease in the majority of individuals. (This study is registered at<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>under registration no. NCT01242670.)<\/jats:p>","DOI":"10.1128\/cvi.00546-14","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T05:58:17Z","timestamp":1419487097000},"page":"267-273","source":"Crossref","is-referenced-by-count":44,"title":["An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial"],"prefix":"10.1128","volume":"22","author":[{"given":"Nina","family":"Wressnigg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikel V. W.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Portsmouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Draxler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"O'Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J. H.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Aaskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Noel","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Aichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2014,12,24]]},"reference":[{"key":"key20180919073757_B1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/B978-0-12-369408-9.00034-2","article-title":"Ross River virus: epidemic polyarthritis","volume-title":"Vaccines for biodefense and emerging and neglected diseases","year":"2009"},{"key":"key20180919073757_B2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1128\/CMR.14.4.909-932.2001","article-title":"Ross River virus transmission, infection, and disease: a cross-disciplinary review","volume":"14","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"key20180919073757_B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tmaid.2010.05.005","article-title":"The viruses of Australia and the risk to tourists","volume":"9","year":"2011","journal-title":"Travel Med Infect Dis"},{"key":"key20180919073757_B4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/01.bor.0000130537.76808.26","article-title":"Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses","volume":"16","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"key20180919073757_B5","volume-title":"National Notifiable Diseases Surveillance System: number of notifications of Ross River virus infection, received from State and Territory health authorities in the period of to 2013 and year-to-date notifications for 2014","author":"Australian Government National Notifiable Diseases Surveillance System","year":"1991"},{"key":"key20180919073757_B6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/vbz.2007.0152","article-title":"Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia","volume":"8","year":"2008","journal-title":"Vector Borne Zoonotic Dis"},{"key":"key20180919073757_B7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1444-0903.2004.00520.x","article-title":"Ross River virus disease in Australia: epidemiology, socioecology and public health response","volume":"34","year":"2004","journal-title":"Intern Med J"},{"key":"key20180919073757_B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4269\/ajtmh.2011.11-0078","article-title":"Vector competence of New Zealand mosquitoes for selected arboviruses","volume":"85","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"key20180919073757_B9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0264-410X(97)00051-0","article-title":"A candidate Ross River virus vaccine: preclinical evaluation","volume":"15","year":"1997","journal-title":"Vaccine"},{"key":"key20180919073757_B10","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1016\/j.vaccine.2011.03.089","article-title":"Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073757_B11","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1016\/j.vaccine.2007.01.103","article-title":"The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073757_B12","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.1016\/j.vaccine.2011.09.125","article-title":"Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073757_B13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/0264-410X(94)90182-1","article-title":"Development of a candidate vaccine against Ross River virus infection","volume":"12","year":"1994","journal-title":"Vaccine"},{"key":"key20180919073757_B14","article-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","volume-title":"U.S. Department of Health and Human Services, Food and Drug Administration","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research","year":"2007"},{"key":"key20180919073757_B15","first-page":"119","article-title":"Persistence in humans of antibody after immunization with four alphavirus vaccines","volume":"3","year":"1979","journal-title":"Asian J Infect Dis"},{"key":"key20180919073757_B16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/infdis\/140.5.708","article-title":"Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)","volume":"140","year":"1979","journal-title":"J Infect Dis"},{"key":"key20180919073757_B17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"key20180919073757_B18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jmv.1890380414","article-title":"Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine","volume":"38","year":"1992","journal-title":"J Med Virol"},{"key":"key20180919073757_B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","year":"1996","journal-title":"Vaccine"},{"key":"key20180919073757_B20","first-page":"241","article-title":"Alphavirus Encephalitides","volume-title":"Medical aspects of biological warfare","year":"2007"},{"key":"key20180919073757_B21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/651271","article-title":"Japanese encephalitis: new options for active immunization","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key20180919073757_B22","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1016\/j.vaccine.2007.08.024","article-title":"Field effectiveness of vaccination against tick-borne encephalitis","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073757_B23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180919073757_B24","first-page":"773","article-title":"Tick-borne encephalitis virus vaccine","volume-title":"Vaccines","year":"2013","edition":"6th ed."},{"key":"key20180919073757_B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0264-410X(03)00563-2","article-title":"Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity","volume":"22","year":"2003","journal-title":"Vaccine"},{"key":"key20180919073757_B26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4161\/hv.5.8.8571","article-title":"Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years","volume":"5","year":"2009","journal-title":"Hum Vaccin"},{"key":"key20180919073757_B27","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1016\/j.vaccine.2011.07.089","article-title":"Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073757_B28","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies","volume":"24","author":"FSME-IMMUN Study Group","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073757_B29","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1016\/j.vaccine.2010.04.075","article-title":"Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073757_B30","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1016\/j.vaccine.2010.04.047","article-title":"Comparison of immunogenicity and safety between two paediatric TBE vaccines","volume":"28","year":"2010","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00546-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:19Z","timestamp":1627591879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00546-14"}},"subtitle":[],"editor":[{"given":"S. A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,24]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,25]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/CVI.00546-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00546-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,24]]}}}